However, when we looked for the type of lymphocytes present in the tumor, we did observe a reduction in CD4 + T cells, alongside with an increase in CD8 + T cells in tumors treated with CM-1758 or upon combination treatment (Fig. 5b and c), whereas no significant differences were observed for the B cell percentage (Fig. 5d). This evidence concerns the gene CD8A and neoplasm.